Berchuck A, Rodriguez G, Kinney R B, Soper J T, Dodge R K, Clarke-Pearson D L, Bast R C
Department of Obstetrics and Gynecology (Division of Gynecologic Oncology), Duke University, Durham, NC 27710.
Am J Obstet Gynecol. 1991 Jan;164(1 Pt 1):15-21. doi: 10.1016/0002-9378(91)90615-x.
Prior studies have shown that overexpression of HER-2/neu occurs in one third of breast and ovarian cancers and that overexpression is associated with poor prognosis. We used a monoclonal antibody to assess immunohistochemically the level of HER-2/neu expression in normal and malignant endometrium. In 24 normal endometrial samples light to moderate (1+ to 2+) staining for HER-2/neu was seen in the glands, and there was no variation in intensity of staining during the menstrual cycle. Among 95 endometrial adenocarcinomas, nine (9%) were found to have heavier staining for HER-2/neu than was seen in normal endometrium (3+). High expression of HER-2/neu was found in 27% of patients with metastatic disease compared with 4% of patients with disease confined to the uterus (p less than 0.005). High HER-2/neu expression also was associated with absence of estrogen receptor (p less than 0.005) and with increased mortality from cancer. Further studies are needed to determine the significance of HER-2/neu overexpression in endometrial cancer.
先前的研究表明，三分之一的乳腺癌和卵巢癌中存在HER-2/neu过表达，且这种过表达与预后不良相关。我们使用单克隆抗体通过免疫组织化学方法评估HER-2/neu在正常和恶性子宫内膜中的表达水平。在24份正常子宫内膜样本中，腺体可见HER-2/neu呈轻至中度（1+至2+）染色，且在月经周期中染色强度无变化。在95例子宫内膜腺癌中，有9例（9%）HER-2/neu染色比正常子宫内膜更重（3+）。与局限于子宫的疾病患者中的4%相比，27%的转移性疾病患者中发现HER-2/neu高表达（p<0.005）。HER-2/neu高表达还与雌激素受体缺失相关（p<0.005），并与癌症死亡率增加相关。需要进一步研究以确定HER-2/neu过表达在子宫内膜癌中的意义。
